Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Grows By 25.5%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 153,000 shares, an increase of 25.5% from the October 15th total of 121,900 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 258,900 shares, the short-interest ratio is presently 0.6 days.

Coeptis Therapeutics Price Performance

Shares of COEP opened at $0.20 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.40 and a quick ratio of 0.55. Coeptis Therapeutics has a 12 month low of $0.15 and a 12 month high of $1.33. The stock’s 50 day moving average is $0.19 and its two-hundred day moving average is $0.24.

Coeptis Therapeutics (NASDAQ:COEP) last issued its quarterly earnings data on Friday, August 16th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, sell-side analysts expect that Coeptis Therapeutics will post -0.26 EPS for the current fiscal year.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.